Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALT03: Pemafibrate in Hypercholesterolemia with Inadequate Statin Response
jRCT2051260070Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pemafibrate in hypercholesterolemia and familial hypercholesterolemia (FH) (3 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percentage change from baseline in LDL-C (direct) at 4 weeks, Percentage change from baseline in LDL-C (direct) at 8 weeks and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on jRCT2051260070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260070.